Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer, a multicentric analysis.

Autor: Francolini G; Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. francolinigiulio@gmail.com., Garlatti P; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Di Cataldo V; Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Triggiani L; Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy., Simoni N; Radiotherapy Unit, Azienda Ospedaliera Universitaria, 43126, Parma, Italy., Detti B; Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Lorenzetti V; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Colombo F; Radiotherapy Unit, Azienda Ospedaliera Universitaria, 43126, Parma, Italy., Morelli V; Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy., Ganovelli M; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Caprara L; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Orsatti C; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Burchini L; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Frosini G; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Bertini N; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Loi M; Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Simontacchi G; Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Greto D; Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Desideri I; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Meattini I; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Livi L; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Jazyk: angličtina
Zdroj: La Radiologia medica [Radiol Med] 2023 Nov; Vol. 128 (11), pp. 1423-1428. Date of Electronic Publication: 2023 Aug 19.
DOI: 10.1007/s11547-023-01701-x
Abstrakt: Background: M1a disease represents an intermediate status between loco-regional relapse and bone metastatic disease. Metastasis directed therapy (MDT), through stereotactic body RT (SBRT) may be offered to patients, aiming to exclusively treat sites of macroscopic relapse and avoiding wide prophylactic treatment volumes. This appears as a viable treatment, especially after the rise of PSMA tailored treatment approaches.
Materials and Methods: Data about patients treated in two different institutions were retrieved from a prospectively collected dataset. All included patients were affected by oligo-recurrent M1a disease after definitive RT or radical prostatectomy, defined as ≤ 3 nodal lesions situated above aortic bifurcation and below renal arteries. Both castration resistant PCa (CRPC) and castration sensitive (CSPC) PCa patients were included. All imaging methods were allowed to detect recurrence (CT scan, Choline or PSMA PET/CT).All sites of recurrences were treated with SBRT.
Results: Median PFS was 10 months (95% CI 8-17). Twelve patients died, with a median OS of 114 months (95% CI 85-114). Out of the 83 recurrences, 2 (2.4%), 11 (13.25%), 36 (43.37%) and 15 (18%) patients had respectively prostate bed only, pelvic nodal, para-aortic or distant relapse. Furthermore, 19 (22.9%) patients experienced a biochemical only relapse with negative imaging at re-staging.
Discussion: MDT conferred a remarkable PFS outcome in a mixed cohort of CSPC and CRPC patients with m1a disease, with an optimal safety profile. Prospective trials are needed in order to compare MDT and ENRT for these patients, allowing to select the best treatment option.
(© 2023. Italian Society of Medical Radiology.)
Databáze: MEDLINE
Externí odkaz: